TipRanks
Go Ultimate55% OFF

Enzychem Lifesciences Corp. (183490) Price & Analysis

183490 Stock Chart & Stats

₩990.00₩0.00(0.00%)
At close: 4:00 PM EDT
KRW 1,000KRW 1,250KRW 1,50029 Dec12 Jan26 Jan9 Feb23 Feb9 Mar23 Mar
Day’s Range
KRW 986.00 - KRW 1,012.00
52-Week Range
KRW 966.00 - KRW 1,766.00
Previous Close
KRW 990.00
Volume
N/A
Average Volume (3M)
0
Market Cap
KRW 76.86B
Enterprise Value
-KRW 18.22B
Total Cash (Recent Filing)
KRW 92.82B
Total Debt (Recent Filing)
KRW 4.84B
Price to Earnings (P/E)
―
Beta
-0.14
Next Earnings
Nov 12, 2026
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Conservative Leverage

Very low leverage and sizable equity provide financial flexibility while the company works through ongoing losses. A conservative capital structure can reduce financing pressure, preserve capacity to fund operations, and offer greater resilience over the next several quarters.

Losses Narrowed From Peak

The reduction in losses from the 2021–2022 worst period indicates some historical progress in controlling the earnings deficit, even though profitability has weakened again recently. This provides a foundation for a potential recovery if operating performance improves.

Cash Flow Sometimes Exceeds Losses

In several years, free cash flow was less negative than accounting earnings, suggesting that non-cash charges or working-capital effects have moderated the cash impact of reported losses at times. That quality-of-earnings feature may help preserve liquidity during recovery efforts.

Bears Say

Persistent Unprofitability

Persistent operating and net losses show that the business has not yet demonstrated a durable path to profitability. Deeply negative margins weaken internal funding capacity, limit reinvestment flexibility, and make future earnings power dependent on a meaningful operating improvement.

Revenue Contraction

A roughly 6% revenue decline in the latest annual period is a negative signal for demand and business momentum, particularly while margins are already weak. Sustained top-line contraction would make fixed-cost absorption harder and further delay progress toward profitability.

Worsening Cash Burn

The sharp deterioration in 2025 operating and free cash flow indicates that losses are consuming substantial liquidity rather than being adequately funded by operations. Continued cash burn can reduce financial flexibility and increase reliance on the balance sheet to sustain the business.

183490 FAQ

What was Enzychem Lifesciences Corp.’s price range in the past 12 months?
Enzychem Lifesciences Corp. lowest stock price was ₩966.00 and its highest was ₩1766.00 in the past 12 months.
What is Enzychem Lifesciences Corp.’s market cap?
Enzychem Lifesciences Corp.’s market cap is ₩76.86B.
When is Enzychem Lifesciences Corp.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Enzychem Lifesciences Corp.’s earnings last quarter?
Enzychem Lifesciences Corp. released its earnings results on Aug 14, 2026. The company reported -₩34.664 earnings per share for the quarter.
Is Enzychem Lifesciences Corp. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Enzychem Lifesciences Corp. pay dividends?
Enzychem Lifesciences Corp. does not currently pay dividends.
What is Enzychem Lifesciences Corp.’s EPS estimate?
Enzychem Lifesciences Corp.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Enzychem Lifesciences Corp. have?
Enzychem Lifesciences Corp. has 84,640,236 shares outstanding.
What happened to Enzychem Lifesciences Corp.’s price movement after its last earnings report?
Enzychem Lifesciences Corp. reported an EPS of -₩34.664 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Enzychem Lifesciences Corp.?
Currently, no hedge funds are holding shares in KR:183490
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology